CD33 and acute myeloid leukemia: Here we demonstrate that gene-modified MSCs are able to (i) express the CD33–CD3 specific bsAb at high levels and (ii) mediate an efficient lysis of AML blasts by human primary T cells of both healthy donors and AML patients.